State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing, China.
Beijing Key Laboratory of Molecular Pharmaceutics, School of Pharmaceutical Sciences, Peking University, Beijing, China.
Nat Commun. 2021 Apr 22;12(1):2385. doi: 10.1038/s41467-021-22678-z.
Nanoparticle internalisation is crucial for the precise delivery of drug/genes to its intracellular targets. Conventional quantification strategies can provide the overall profiling of nanoparticle biodistribution, but fail to unambiguously differentiate the intracellularly bioavailable particles from those in tumour intravascular and extracellular microenvironment. Herein, we develop a binary ratiometric nanoreporter (BiRN) that can specifically convert subtle pH variations involved in the endocytic events into digitised signal output, enabling the accurately quantifying of cellular internalisation without introducing extracellular contributions. Using BiRN technology, we find only 10.7-28.2% of accumulated nanoparticles are internalised into intracellular compartments with high heterogeneity within and between different tumour types. We demonstrate the therapeutic responses of nanomedicines are successfully predicted based on intracellular nanoparticle exposure rather than the overall accumulation in tumour mass. This nonlinear optical nanotechnology offers a valuable imaging tool to evaluate the tumour targeting of new nanomedicines and stratify patients for personalised cancer therapy.
纳米颗粒内化对于将药物/基因精确递送到其细胞内靶标至关重要。传统的定量策略可以提供纳米颗粒生物分布的整体分析,但无法明确区分细胞内可用的颗粒与肿瘤血管内和细胞外微环境中的颗粒。在此,我们开发了一种二进制比率纳米报告器(BiRN),它可以特异性地将涉及内吞作用的微小 pH 变化转化为数字化信号输出,从而能够准确地定量细胞内化,而不会引入细胞外的贡献。使用 BiRN 技术,我们发现只有 10.7-28.2%的累积纳米颗粒被内化到细胞内隔室中,不同肿瘤类型之间存在高度异质性。我们证明,纳米药物的治疗反应可以基于细胞内纳米颗粒暴露而不是肿瘤质量中的整体积累来成功预测。这项非线性光学纳米技术为评估新型纳米药物的肿瘤靶向性和为个体化癌症治疗分层患者提供了有价值的成像工具。